Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Ursula A. Matulonis, MD


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Chief, Division of Gynecologic Oncology
  • Brock-Wilson Family Chair
  • Institute Physician
  • Professor of Medicine, Harvard Medical School

Centers/Programs

Clinical Interests

  • Gynecologic malignancies
  • New therapies for gynecologic cancers

Contact Information

  • Appointments617-632-2175
  • Office Phone Number617-632-2334
  • Fax617-632-3479

Bio

Ursula A. Matulonis, MD is Chief, Division of Gynecologic Oncology at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School. Her research focuses on targeted therapies for gynecologic malignancies, with a specific interest in the genetic changes in ovarian cancer and how that can lead to rationale targeted drug selection. Dr. Matulonis is the Principal Investigator of several clinical trials and translational studies for ovarian cancer. Dr. Matulonis is a Co-PI on an ovarian cancer SPORE project entitled “Identification of Oncogenic Mutations in Ovarian Cancer,” and a Co-PI on the project “Genetic relationships between breast and ovarian cancer” that is funded by the Breast Cancer Research Foundation. She is also a past recipient of a DF/HCC Ovarian Cancer SPORE Developmental Grant entitled “Genetic Fingerprinting of Ovarian Cancer.”

Dr. Matulonis serves on the National Comprehensive Cancer Network Ovarian Cancer Recommendation and Guideline Committee for both ovarian cancer and for the treatment of anemia, the Gynecologic Oncology Group Quality of Life Committee, a member of The Cancer Genome Atlas Project (TCGA) Endometrial Analysis Working Group, and is Medical Director and Board Member for the non-profit organization Ovations for the Cure. She is a recipient of the Dennis Thompson Compassionate Care Scholar award, the Lee Nadler “Extra Mile” Award, and was named one of Boston’s Best Physicians in Medical Oncology by Boston Magazine numerous times. She serves on the editorial board of the Journal of Clinical Oncology.

After receiving her MD from Albany Medical College, she completed an internship and residency at the University of Pittsburgh, followed by a medical oncology fellowship at Dana-Farber.

Board Certification:

  • Internal Medicine, 2000
  • Medical Oncology, 2003

Fellowship:

  • Dana-Farber Cancer Institute, Medical Oncology

Residency:

  • University of Pittsburgh, Internal Medicine

Medical School:

  • Albany Medical College

Recent Awards:

  • Partners in Excellence Award, Partners Health Care 2010
  • Lee Nadler "Extra Mile" Award 2009
  • "Boston Magazine" Best Doctors 2009
  • Partners in Excellence Award, Partners Health Care 2000
  • Dennis Thompson Compassionate Care Scholar, Brigham and Women's Hospital 2000

Research

Clinical Trials in Gynecologic Malignancies

The Medical Gynecologic Oncology Program serves as the infrastructure for clinical and translational research at Dana-Farber Cancer Institute. Our research involves testing novel drugs and biologics in newly diagnosed as well as recurrent gynecologic tumors: ovarian, endometrial, cervical, vaginal, and vulvar cancers. A list of ongoing clinical trials is available via our website. Our integrated team of medical oncologists, gynecologic oncology surgeons, radiation oncologists, gynecologic oncology pathologists, clinical research team, and basic science researchers is immersed in a number of translational projects. Examples of ongoing projects in 2010 include the expression profiling and genotyping of ovarian cancer, the study of circulating tumor cells in ovarian cancer, investigation of HER3 expression and signalling and therapeutic potential of HER3, and the study of the PI3 kinase pathway in endometrial cancer.

Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy. Eur J Cancer. 2021 Jul 19; 154:190-200.
View in: PubMed

Sequential Phase II clinical trials evaluating CRLX101 as monotherapy and in combination with bevacizumab in recurrent ovarian cancer. Gynecol Oncol. 2021 Jul 06.
View in: PubMed

Enhanced Efficacy of Aurora Kinase Inhibitors in G2/M Checkpoint Deficient TP53 Mutant Uterine Carcinomas Is Linked to the Summation of LKB1-AKT-p53 Interactions. Cancers (Basel). 2021 May 03; 13(9).
View in: PubMed

Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis. Cancer. 2021 Jul 15; 127(14):2432-2441.
View in: PubMed

Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials. Gynecol Oncol. 2021 Jun; 161(3):653-659.
View in: PubMed

Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma. J Clin Oncol. 2021 May 10; 39(14):1531-1539.
View in: PubMed

Disease Distribution at Presentation Impacts Benefit of IP Chemotherapy Among Patients with Advanced-Stage Ovarian Cancer. Ann Surg Oncol. 2021 Mar 08.
View in: PubMed

Stepping into survivorship pilot study: Harnessing mobile health and principles of behavioral economics to increase physical activity in ovarian cancer survivors. Gynecol Oncol. 2021 May; 161(2):581-586.
View in: PubMed

Case Report: Frontoparietal Metastasis From a Primary Fallopian Tube Carcinoma. Front Surg. 2021; 8:594570.
View in: PubMed

Embedding a genetic counselor into oncology clinics improves testing rates and timeliness for women with ovarian cancer. Gynecol Oncol. 2021 02; 160(2):457-463.
View in: PubMed

Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer. Cancer Res. 2021 01 01; 81(1):158-173.
View in: PubMed

Detection of ERBB2 amplification in uterine serous carcinoma by next-generation sequencing: an approach highly concordant with standard assays. Mod Pathol. 2021 03; 34(3):603-612.
View in: PubMed

Clinical assays for assessment of homologous recombination DNA repair deficiency. Gynecol Oncol. 2020 12; 159(3):887-898.
View in: PubMed

Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial. Gynecol Oncol. 2020 11; 159(2):442-448.
View in: PubMed

Homologous recombination deficiency real-time clinical assays, ready or not? Gynecol Oncol. 2020 12; 159(3):877-886.
View in: PubMed

Deciphering serous ovarian carcinoma histopathology and platinum response by convolutional neural networks. BMC Med. 2020 08 18; 18(1):236.
View in: PubMed

Combined pembrolizumab and pegylated liposomal doxorubicin in platinum resistant ovarian cancer: A phase 2 clinical trial. Gynecol Oncol. 2020 10; 159(1):72-78.
View in: PubMed

Mural nodules in mucinous ovarian tumors represent a morphologic spectrum of clonal neoplasms: a morphologic, immunohistochemical, and molecular analysis of 13 cases. Mod Pathol. 2021 03; 34(3):613-626.
View in: PubMed

Author Correction: A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nat Med. 2020 Aug; 26(8):1307.
View in: PubMed

PARP Inhibitor Resistance Mechanisms and Implications for Post-Progression Combination Therapies. Cancers (Basel). 2020 Jul 25; 12(8).
View in: PubMed

Combined CDK4/6 and PD-1 Inhibition in Refractory SMARCA4-Deficient Small-Cell Carcinoma of the Ovary, Hypercalcemic Type. JCO Precis Oncol. 2020; 4:736-742.
View in: PubMed

A single-cell landscape of high-grade serous ovarian cancer. Nat Med. 2020 08; 26(8):1271-1279.
View in: PubMed

Emerging drugs for the treatment of ovarian cancer: a focused review of PARP inhibitors. Expert Opin Emerg Drugs. 2020 06; 25(2):165-188.
View in: PubMed

Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020 07; 21(7):957-968.
View in: PubMed

Differential blood count as triage tool in evaluation of pelvic masses. Int J Gynecol Cancer. 2021 May; 31(5):733-743.
View in: PubMed

Author Correction: Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020 05 18; 11(1):2543.
View in: PubMed

A single-cell and single-nucleus RNA-Seq toolbox for fresh and frozen human tumors. Nat Med. 2020 05; 26(5):792-802.
View in: PubMed

Genomic Determinants of De Novo Resistance to Immune Checkpoint Blockade in Mismatch Repair-Deficient Endometrial Cancer. JCO Precis Oncol. 2020; 4:492-497.
View in: PubMed

COVID-19 and ovarian cancer: Exploring alternatives to intravenous (IV) therapies. Gynecol Oncol. 2020 07; 158(1):34-36.
View in: PubMed

Author Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. Nat Commun. 2020 Apr 17; 11(1):1940.
View in: PubMed

Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer. Nat Commun. 2020 03 19; 11(1):1459.
View in: PubMed

An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers. BMC Cancer. 2020 Mar 12; 20(1):197.
View in: PubMed

Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer. Ann Oncol. 2020 05; 31(5):590-598.
View in: PubMed

Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2020 05; 157(2):379-385.
View in: PubMed

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035). Gynecol Oncol Rep. 2020 May; 32:100546.
View in: PubMed

Phase II, 2-stage, 2-arm, PIK3CA mutation stratified trial of MK-2206 in recurrent endometrial cancer. Int J Cancer. 2020 07 15; 147(2):413-422.
View in: PubMed

A Randomized Phase II Trial of Epigenetic Priming with Guadecitabine and Carboplatin in Platinum-resistant, Recurrent Ovarian Cancer. Clin Cancer Res. 2020 03 01; 26(5):1009-1016.
View in: PubMed

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol. 2019 Apr; 30(4):551-557.
View in: PubMed

Correction to: "Safety and dose modification for patients receiving niraparib". Ann Oncol. 2019 May; 30(5):859.
View in: PubMed

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019 Jul; 30(7):1080-1087.
View in: PubMed

Prediagnosis and postdiagnosis smoking and survival following diagnosis with ovarian cancer. Int J Cancer. 2020 08 01; 147(3):736-746.
View in: PubMed

Assessment of Combined Nivolumab and Bevacizumab in Relapsed Ovarian Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2019 12 01; 5(12):1731-1738.
View in: PubMed

Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib. J Cancer Res Clin Oncol. 2020 Feb; 146(2):503-514.
View in: PubMed

Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations. Gynecol Oncol. 2020 02; 156(2):488-497.
View in: PubMed

Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial. J Clin Oncol. 2019 12 01; 37(34):3183-3191.
View in: PubMed

Phase II Study of Avelumab in Patients With Mismatch Repair Deficient and Mismatch Repair Proficient Recurrent/Persistent Endometrial Cancer. J Clin Oncol. 2019 10 20; 37(30):2786-2794.
View in: PubMed

Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer. Mol Cancer Res. 2019 11; 17(11):2281-2293.
View in: PubMed

The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition. Clin Cancer Res. 2019 10 15; 25(20):6127-6140.
View in: PubMed

Results of an abbreviated Phase Ib study of the HDAC6 inhibitor ricolinostat and paclitaxel in recurrent ovarian, fallopian tube, or primary peritoneal cancer. Gynecol Oncol Rep. 2019 Aug; 29:118-122.
View in: PubMed

Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8+ T cells compared with women with BRCA wild-type disease during the early disease course. Oncol Lett. 2019 Oct; 18(4):3914-3924.
View in: PubMed

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma. JAMA Oncol. 2019 Aug 01; 5(8):1141-1149.
View in: PubMed

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study. Ann Oncol. 2019 07 01; 30(7):1080-1087.
View in: PubMed

Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer. Am J Obstet Gynecol. 2019 12; 221(6):625.e1-625.e14.
View in: PubMed

Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer. N Engl J Med. 2019 06 13; 380(24):2317-2326.
View in: PubMed

Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial. J Clin Oncol. 2019 11 10; 37(32):2968-2973.
View in: PubMed

Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer. Gynecol Oncol. 2019 07; 154(1):95-101.
View in: PubMed

Safety and dose modification for patients receiving niraparib. Ann Oncol. 2019 05 01; 30(5):859.
View in: PubMed

Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC). Int J Gynecol Pathol. 2019 May; 38(3):230-240.
View in: PubMed

Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy? Gynecol Oncol. 2019 07; 154(1):236-245.
View in: PubMed

Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 2019 05; 20(5):636-648.
View in: PubMed

Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol. 2019 04 01; 30(4):551-557.
View in: PubMed

Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer. Gynecol Oncol. 2019 06; 153(3):471-478.
View in: PubMed

Olaparib and a-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol. 2019 04; 20(4):570-580.
View in: PubMed

Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer. 2019 06 15; 125(12):1963-1972.
View in: PubMed

Final report on serial phase II trials of all-intraperitoneal chemotherapy with or without bevacizumab for women with newly diagnosed, optimally cytoreduced carcinoma of Müllerian origin. Gynecol Oncol. 2019 05; 153(2):223-229.
View in: PubMed

POLE-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure. Gynecol Oncol Rep. 2019 May; 28:15-17.
View in: PubMed

Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness. Mol Cancer Ther. 2019 03; 18(3):642-655.
View in: PubMed

Efficacy and safety of niraparib as maintenance treatment in older patients (=?70?years) with recurrent ovarian cancer: Results from the ENGOT-OV16/NOVA trial. Gynecol Oncol. 2019 03; 152(3):560-567.
View in: PubMed

Alisertib in Combination With Weekly Paclitaxel in Patients With Advanced Breast Cancer or Recurrent Ovarian Cancer: A Randomized Clinical Trial. JAMA Oncol. 2019 01 01; 5(1):e183773.
View in: PubMed

A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2019 03; 152(3):548-553.
View in: PubMed

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. Cell Rep. 2018 12 11; 25(11):2972-2980.e5.
View in: PubMed

Targeting DNA Damage Response and Repair as a Therapeutic Strategy for Ovarian Cancer. Hematol Oncol Clin North Am. 2018 12; 32(6):997-1010.
View in: PubMed

Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13. Elife. 2018 11 13; 7.
View in: PubMed

Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine. Clin Cancer Res. 2019 03 15; 25(6):1727-1736.
View in: PubMed

Targeted Next-Generation Sequencing Reveals Clinically Actionable BRAF and ESR1 Mutations in Low-Grade Serous Ovarian Carcinoma. JCO Precis Oncol. 2018; 2018.
View in: PubMed

Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer. 2018 10; 119(9):1075-1085.
View in: PubMed

Ovarian Cancer. Hematol Oncol Clin North Am. 2018 12; 32(6):xiii-xiv.
View in: PubMed

Multiple Myeloma Masquerading as Ovarian Carcinosarcoma Metastases: A Case Report and Review of the Approach to Multiple Myeloma Screening and Diagnosis. Case Rep Hematol. 2018; 2018:3029650.
View in: PubMed

Prediction of DNA Repair Inhibitor Response in Short-Term Patient-Derived Ovarian Cancer Organoids. Cancer Discov. 2018 11; 8(11):1404-1421.
View in: PubMed

BRAF and AXL oncogenes drive RIPK3 expression loss in cancer. PLoS Biol. 2018 08; 16(8):e2005756.
View in: PubMed

Safety and dose modification for patients receiving niraparib. Ann Oncol. 2018 08 01; 29(8):1784-1792.
View in: PubMed

Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a cohort study. Lancet Oncol. 2018 08; 19(8):1107-1116.
View in: PubMed

Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2018 08; 19(8):1117-1125.
View in: PubMed

Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor. Gynecol Oncol. 2018 08; 150(2):219-226.
View in: PubMed

PARP Inhibitors in Ovarian Cancer: A Trailblazing and Transformative Journey. Clin Cancer Res. 2018 09 01; 24(17):4062-4065.
View in: PubMed

Management of newly diagnosed or recurrent ovarian cancer. Clin Adv Hematol Oncol. 2018 Jun; 16(6):426-437.
View in: PubMed

Multifaceted Impact of MicroRNA 493-5p on Genome-Stabilizing Pathways Induces Platinum and PARP Inhibitor Resistance in BRCA2-Mutated Carcinomas. Cell Rep. 2018 04 03; 23(1):100-111.
View in: PubMed

Publisher Correction: Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. Nat Commun. 2018 02 07; 9(1):628.
View in: PubMed

The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities. Gynecol Oncol. 2018 04; 149(1):214-220.
View in: PubMed

The NCI-MATCH trial and precision medicine in gynecologic cancers. Gynecol Oncol. 2018 03; 148(3):585-590.
View in: PubMed

Management of the toxicities of common targeted therapeutics for gynecologic cancers. Gynecol Oncol. 2018 03; 148(3):591-600.
View in: PubMed

Epigenetic Reprogramming Strategies to Reverse Global Loss of 5-Hydroxymethylcytosine, a Prognostic Factor for Poor Survival in High-grade Serous Ovarian Cancer. Clin Cancer Res. 2018 03 15; 24(6):1389-1401.
View in: PubMed

Nanoparticle conjugates of a highly potent toxin enhance safety and circumvent platinum resistance in ovarian cancer. Nat Commun. 2017 12 18; 8(1):2166.
View in: PubMed

A review of mirvetuximab soravtansine in the treatment of platinum-resistant ovarian cancer. Future Oncol. 2018 Jan; 14(2):123-136.
View in: PubMed

Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor. EBioMedicine. 2017 Nov; 25:50-57.
View in: PubMed

Systems analysis of apoptotic priming in ovarian cancer identifies vulnerabilities and predictors of drug response. Nat Commun. 2017 08 28; 8(1):365.
View in: PubMed

Characterization of folate receptor alpha (FRa) expression in archival tumor and biopsy samples from relapsed epithelial ovarian cancer patients: A phase I expansion study of the FRa-targeting antibody-drug conjugate mirvetuximab soravtansine. Gynecol Oncol. 2017 11; 147(2):402-407.
View in: PubMed

Highlights in Ovarian Cancer From the 2017 American Society of Clinical Oncology Annual Meeting: Commentary. Clin Adv Hematol Oncol. 2017 Aug; 15 Suppl 7(8):13-17.
View in: PubMed

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. Oncotarget. 2017 Jul 18; 8(29):47154-47160.
View in: PubMed

Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor a-targeting antibody-drug conjugate, in patients with solid tumors. Cancer. 2017 Aug 15; 123(16):3080-3087.
View in: PubMed

PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist? Ann Oncol. 2017 03 01; 28(3):443-447.
View in: PubMed

Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Ann Oncol. 2017 03 01; 28(3):512-518.
View in: PubMed

Niraparib in Recurrent Ovarian Cancer. N Engl J Med. 2017 02 23; 376(8):801-2.
View in: PubMed

Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization. Clin Cancer Res. 2017 Aug 01; 23(15):4086-4094.
View in: PubMed

PARP inhibitors in ovarian cancer: evidence, experience and clinical potential. Ther Adv Med Oncol. 2017 Apr; 9(4):253-267.
View in: PubMed

Clear cell ovarian cancers with microsatellite instability: A unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1/PD-L1 expression. Oncoimmunology. 2017; 6(2):e1277308.
View in: PubMed

Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2017 Apr 01; 35(10):1112-1118.
View in: PubMed

Institutional implementation of clinical tumor profiling on an unselected cancer population. JCI Insight. 2016 11 17; 1(19):e87062.
View in: PubMed

Use and Effectiveness of Neoadjuvant Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol. 2016 11 10; 34(32):3854-3863.
View in: PubMed

Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer. Br J Cancer. 2016 Nov 22; 115(11):1313-1320.
View in: PubMed

Use of CA-125 Tests and Computed Tomographic Scans for Surveillance in Ovarian Cancer. JAMA Oncol. 2016 Nov 01; 2(11):1427-1433.
View in: PubMed

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody-drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer. Ann Oncol. 2016 11; 27(11):2124-2130.
View in: PubMed

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016 12 01; 375(22):2154-2164.
View in: PubMed

Biomarkers of Response and Resistance to DNA Repair Targeted Therapies. Clin Cancer Res. 2016 Dec 01; 22(23):5651-5660.
View in: PubMed

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 2016 Nov; 17(11):1579-1589.
View in: PubMed

A multicenter, single-arm, open-label, phase 2 study of apitolisib (GDC-0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study). Cancer. 2016 Nov 15; 122(22):3519-3528.
View in: PubMed

Next-Generation Sequencing: Role in Gynecologic Cancers. J Natl Compr Canc Netw. 2016 09; 14(9):1165-73.
View in: PubMed

Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 09; 14(9):1134-63.
View in: PubMed

Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics. Clin Cancer Res. 2017 Mar 01; 23(5):1263-1273.
View in: PubMed

Ovarian cancer. Nat Rev Dis Primers. 2016 08 25; 2:16061.
View in: PubMed

Prognostic importance of human papillomavirus (HPV) and p16 positivity in squamous cell carcinoma of the vulva treated with radiotherapy. Gynecol Oncol. 2016 08; 142(2):293-8.
View in: PubMed

Morphologic correlates of molecular alterations in extrauterine Müllerian carcinomas. Mod Pathol. 2016 08; 29(8):893-903.
View in: PubMed

What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment? Curr Oncol Rep. 2016 May; 18(5):29.
View in: PubMed

Olaparib maintenance therapy in patients with platinum-sensitive, relapsed serous ovarian cancer and a BRCA mutation: Overall survival adjusted for postprogression poly(adenosine diphosphate ribose) polymerase inhibitor therapy. Cancer. 2016 Jun 15; 122(12):1844-52.
View in: PubMed

Moving beyond the platinum sensitive/resistant paradigm for patients with recurrent ovarian cancer. Gynecol Oncol. 2016 06; 141(3):405-409.
View in: PubMed

Precision medicine. Gynecol Oncol. 2016 Apr; 141(1):1.
View in: PubMed

Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget. 2016 Mar 22; 7(12):13587-98.
View in: PubMed

Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer. Expert Opin Investig Drugs. 2016; 25(5):597-611.
View in: PubMed

Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germline BRCA1/2 mutation: a multistudy analysis of response rates and safety. Ann Oncol. 2016 06; 27(6):1013-1019.
View in: PubMed

Safety, Costs, and Efficacy of Rapid Drug Desensitizations to Chemotherapy and Monoclonal Antibodies. J Allergy Clin Immunol Pract. 2016 May-Jun; 4(3):497-504.
View in: PubMed

Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. Cell Rep. 2016 Jan 26; 14(3):429-439.
View in: PubMed

Risk stratification and skin testing to guide re-exposure in taxane-induced hypersensitivity reactions. J Allergy Clin Immunol. 2016 Apr; 137(4):1154-1164.e12.
View in: PubMed

Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse model. Oncoimmunology. 2016 Mar; 5(3):e1090075.
View in: PubMed

Genomic testing and precision medicine--What does this mean for gynecologic oncology? Gynecol Oncol. 2016 Jan; 140(1):3-5.
View in: PubMed

Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1. JAMA Oncol. 2015 Dec; 1(9):1319-23.
View in: PubMed

Use and Effectiveness of Intraperitoneal Chemotherapy for Treatment of Ovarian Cancer. J Clin Oncol. 2015 Sep 10; 33(26):2841-7.
View in: PubMed

Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. Cancer Chemother Pharmacol. 2015 Aug; 76(2):417-23.
View in: PubMed

Bevacizumab in newly diagnosed ovarian cancer. Lancet Oncol. 2015 Aug; 16(8):876-8.
View in: PubMed

The PARP1 inhibitor BMN 673 exhibits immunoregulatory effects in a Brca1(-/-) murine model of ovarian cancer. Biochem Biophys Res Commun. 2015 Aug 07; 463(4):551-6.
View in: PubMed

CECs and IL-8 Have Prognostic and Predictive Utility in Patients with Recurrent Platinum-Sensitive Ovarian Cancer: Biomarker Correlates from the Randomized Phase-2 Trial of Olaparib and Cediranib Compared with Olaparib in Recurrent Platinum-Sensitive Ovarian Cancer. Front Oncol. 2015; 5:123.
View in: PubMed

NRG Oncology/RTOG 0921: A phase 2 study of postoperative intensity-modulated radiotherapy with concurrent cisplatin and bevacizumab followed by carboplatin and paclitaxel for patients with endometrial cancer. Cancer. 2015 Jul 01; 121(13):2156-63.
View in: PubMed

Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell. 2015 Feb 26; 160(5):977-989.
View in: PubMed

A unique subset of epithelial ovarian cancers with platinum sensitivity and PARP inhibitor resistance. Cancer Res. 2015 Feb 15; 75(4):628-34.
View in: PubMed

Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer. Clin Cancer Res. 2015 Feb 15; 21(4):808-18.
View in: PubMed

Phase II study of the PI3K inhibitor pilaralisib (SAR245408; XL147) in patients with advanced or recurrent endometrial carcinoma. Gynecol Oncol. 2015 Feb; 136(2):246-53.
View in: PubMed

Intermediate clinical endpoints: a bridge between progression-free survival and overall survival in ovarian cancer trials. Cancer. 2015 Jun 01; 121(11):1737-46.
View in: PubMed

New strategies in ovarian cancer: translating the molecular complexity of ovarian cancer into treatment advances. Clin Cancer Res. 2014 Oct 15; 20(20):5150-6.
View in: PubMed

POLE mutations as an alternative pathway for microsatellite instability in endometrial cancer: implications for Lynch syndrome testing. Cancer. 2015 Feb 01; 121(3):331-4.
View in: PubMed

Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study. Lancet Oncol. 2014 Oct; 15(11):1207-14.
View in: PubMed

A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. Gynecol Oncol. 2014 Sep; 134(3):478-85.
View in: PubMed

A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer. J Clin Oncol. 2014 Jun 20; 32(18_suppl):LBA5500.
View in: PubMed

ß-Catenin mutations in recurrent FIGO IA grade I endometrioid endometrial cancers. Gynecol Oncol. 2014 Aug; 134(2):426-7.
View in: PubMed

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014 Jul; 15(8):852-61.
View in: PubMed

Sublethal concentrations of 17-AAG suppress homologous recombination DNA repair and enhance sensitivity to carboplatin and olaparib in HR proficient ovarian cancer cells. Oncotarget. 2014 May 15; 5(9):2678-87.
View in: PubMed

Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. J Clin Invest. 2014 Jun; 124(6):2611-25.
View in: PubMed

PARP inhibitors in ovarian cancer: current status and future promise. Gynecol Oncol. 2014 May; 133(2):362-9.
View in: PubMed

Chemotherapy hypersensitivity reactions in ovarian cancer. J Natl Compr Canc Netw. 2014 Mar 01; 12(3):389-402.
View in: PubMed

Current status and evolution of preclinical drug development models of epithelial ovarian cancer. Front Oncol. 2013 Dec 11; 3:296.
View in: PubMed

Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations. PLoS One. 2013; 8(11):e80023.
View in: PubMed

Clinical predictors of long-term survival for stage IVB uterine papillary serous carcinoma confined to the abdomen. Gynecol Oncol. 2014 Jan; 132(1):65-9.
View in: PubMed

A prospective feasibility study of radiation and concurrent bevacizumab for recurrent endometrial cancer. Gynecol Oncol. 2014 Jan; 132(1):55-60.
View in: PubMed

Ovarian cancer, version 2.2013. J Natl Compr Canc Netw. 2013 Oct 01; 11(10):1199-209.
View in: PubMed

Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix. Cancer. 2013 Nov 01; 119(21):3776-83.
View in: PubMed

Predictive value of circulating tumor cells (CTCs) in newly-diagnosed and recurrent ovarian cancer patients. Gynecol Oncol. 2013 Nov; 131(2):352-6.
View in: PubMed

Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. Clin Cancer Res. 2013 Oct 01; 19(19):5485-93.
View in: PubMed

Hopelessness and complementary therapy use in patients with ovarian cancer. Cancer Nurs. 2013 Jul-Aug; 36(4):256-64.
View in: PubMed

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer. 2013 Sep; 49(14):2972-8.
View in: PubMed

Vaginal brachytherapy for early stage uterine papillary serous and clear cell endometrial cancer. Gynecol Oncol. 2013 Apr; 129(1):18-21.
View in: PubMed

The Feasibility and Effects of Acupuncture on Quality of Life Scores During Chemotherapy in Ovarian Cancer: Results from a Pilot, Randomized Sham-Controlled Trial. Med Acupunct. 2012 12; 24(4):233-240.
View in: PubMed

Ovarian cancer, version 3.2012. J Natl Compr Canc Netw. 2012 Nov 01; 10(11):1339-49.
View in: PubMed

Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci U S A. 2012 Oct 23; 109(43):E2939-48.
View in: PubMed

Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res. 2012 Oct 15; 18(20):5806-15.
View in: PubMed

ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer. Eur J Cancer. 2013 Jan; 49(1):121-31.
View in: PubMed

A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecol Oncol. 2013 Feb; 128(2):215-20.
View in: PubMed

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecol Oncol. 2012 Oct; 127(1):63-9.
View in: PubMed

Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. Gynecol Oncol. 2012 Oct; 127(1):141-6.
View in: PubMed

Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw. 2012 May; 10(5):628-53.
View in: PubMed

Sequential bevacizumab and oral cyclophosphamide for recurrent ovarian cancer. Gynecol Oncol. 2012 Jul; 126(1):41-6.
View in: PubMed

Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med. 2012 Apr 12; 366(15):1382-92.
View in: PubMed

Bevacizumab rechallenge after first line maintenance bevacizumab. Gynecol Oncol. 2012 May; 125(2):510-1.
View in: PubMed

Photo quiz. Rash in a patient with ovarian cancer. Clin Infect Dis. 2012 Feb 15; 54(4):538, 575-6.
View in: PubMed

Angiogenic mRNA and microRNA gene expression signature predicts a novel subtype of serous ovarian cancer. PLoS One. 2012; 7(2):e30269.
View in: PubMed

Changes in serum CA-125 can predict optimal cytoreduction to no gross residual disease in patients with advanced stage ovarian cancer treated with neoadjuvant chemotherapy. Gynecol Oncol. 2012 May; 125(2):362-6.
View in: PubMed

New biologic agents for the treatment of gynecologic cancers. Hematol Oncol Clin North Am. 2012 Feb; 26(1):133-56.
View in: PubMed

Young women diagnosed with early-stage ovarian cancer or borderline malignancy of the ovary: a focus on fertility and sexual function. J Psychosoc Oncol. 2012; 30(4):387-401.
View in: PubMed

Clinical characteristics and outcomes of BRCA-associated ovarian cancer: genotype and survival. Cancer Genet. 2012 Jan-Feb; 205(1-2):34-41.
View in: PubMed

Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol. 2012 Feb 01; 30(4):372-9.
View in: PubMed

Anti-angiogenic agents in ovarian cancer: dawn of a new era? Curr Oncol Rep. 2011 Dec; 13(6):450-8.
View in: PubMed

Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science. 2011 Nov 25; 334(6059):1129-33.
View in: PubMed

The importance of chemotherapy and radiation in uterine papillary serous carcinoma. Gynecol Oncol. 2011 Dec; 123(3):542-7.
View in: PubMed

High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. PLoS One. 2011; 6(9):e24433.
View in: PubMed

Urinary MMP-2 and MMP-9 predict the presence of ovarian cancer in women with normal CA125 levels. Gynecol Oncol. 2011 Nov; 123(2):295-300.
View in: PubMed

NCCN Biosimilars White Paper: regulatory, scientific, and patient safety perspectives. J Natl Compr Canc Netw. 2011 Sep; 9 Suppl 4:S1-22.
View in: PubMed

A phase II study of ENMD-2076 in platinum-resistant ovarian cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):5021.
View in: PubMed

A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-resistant recurrent ovarian cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):5005.
View in: PubMed

A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):5004.
View in: PubMed

The use of bevacizumab and concurrent radiation for recurrent gynecologic cancers. J Clin Oncol. 2011 May 20; 29(15_suppl):5101.
View in: PubMed

Phase II randomized placebo-controlled study of olaparib (AZD2281) in patients with platinum-sensitive relapsed serous ovarian cancer (PSR SOC). J Clin Oncol. 2011 May 20; 29(15_suppl):5003.
View in: PubMed

A phase I trial of the PARP inhibitor olaparib (AZD2281) in combination with the antiangiogenic cediranib (AZD2171) in recurrent ovarian or triple-negative breast cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):5028.
View in: PubMed

Bevacizumab and its use in epithelial ovarian cancer. Future Oncol. 2011 Mar; 7(3):365-79.
View in: PubMed

Epithelial ovarian cancer. J Natl Compr Canc Netw. 2011 Jan; 9(1):82-113.
View in: PubMed

CA125 immune complexes in ovarian cancer patients with low CA125 concentrations. Clin Chem. 2010 Dec; 56(12):1889-92.
View in: PubMed

Influence of patients' preferences and treatment site on cancer patients' end-of-life care. Cancer. 2010 Oct 01; 116(19):4656-63.
View in: PubMed

Place of death: correlations with quality of life of patients with cancer and predictors of bereaved caregivers' mental health. J Clin Oncol. 2010 Oct 10; 28(29):4457-64.
View in: PubMed

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet. 2010 Jul 24; 376(9737):245-51.
View in: PubMed

New advances in ovarian cancer. Oncology (Williston Park). 2010 Jul; 24(8):721-8.
View in: PubMed

Acupuncture as palliative therapy for physical symptoms and quality of life for advanced cancer patients. Integr Cancer Ther. 2010 Jun; 9(2):158-67.
View in: PubMed

Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer. Int J Clin Oncol. 2010 Aug; 15(4):390-8.
View in: PubMed

Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival. Neoplasia. 2010 Feb; 12(2):161-72.
View in: PubMed

Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor. Clin J Am Soc Nephrol. 2010 Mar; 5(3):477-83.
View in: PubMed

Long-term adjustment of survivors of ovarian cancer treated for advanced-stage disease. J Psychosoc Oncol. 2010; 28(5):451-69.
View in: PubMed

Whole-genome gene expression profiling of formalin-fixed, paraffin-embedded tissue samples. PLoS One. 2009 Dec 03; 4(12):e8162.
View in: PubMed

Review: erythropoiesis-stimulating agents increase mortality in patients with cancer. Evid Based Med. 2009 Dec; 14(6):182.
View in: PubMed

Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors. Gynecol Oncol. 2010 Feb; 116(2):168-72.
View in: PubMed

Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol. 2010 Jan 01; 28(1):154-9.
View in: PubMed

Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. J Clin Oncol. 2010 Mar 01; 28(7):1215-23.
View in: PubMed

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009 Nov 20; 27(33):5601-6.
View in: PubMed

Prognosis and hormone receptor status in older and younger patients with advanced-stage papillary serous ovarian carcinoma. Gynecol Oncol. 2009 Dec; 115(3):401-6.
View in: PubMed

ACP Journal Club. Review: Erythropoiesis-stimulating agents increase mortality in patients with cancer. Ann Intern Med. 2009 Sep 15; 151(6):JC3-7.
View in: PubMed

Acupuncture for chemotherapy-induced neutropenia in patients with gynecologic malignancies: a pilot randomized, sham-controlled clinical trial. J Altern Complement Med. 2009 Jul; 15(7):745-53.
View in: PubMed

Comparison of the quality of life of early and advanced stage ovarian cancer survivors. Gynecol Oncol. 2009 Aug; 114(2):353-9.
View in: PubMed

A phase II trial of voreloxin in women with platinum-resistant ovarian cancer. J Clin Oncol. 2009 May 20; 27(15_suppl):5559.
View in: PubMed

Phase II prospective study of paclitaxel and carboplatin in older patients with newly diagnosed Müllerian tumors. Gynecol Oncol. 2009 Feb; 112(2):394-9.
View in: PubMed

Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7667-73.
View in: PubMed

Phase II study of carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 Dec 10; 26(35):5761-6.
View in: PubMed

Ovarian cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2008 Sep; 6(8):766-94.
View in: PubMed

Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw. 2008 Jul; 6(6):536-64.
View in: PubMed

Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol. 2008 Sep; 122(3):574-80.
View in: PubMed

Anaphylactic and anaphylactoid reactions to chemotherapy: outcomes and safety of rapid intravenous and intraperitoneal desensitizations in 413 cases. J Clin Oncol. 2008 May 20; 26(15_suppl):5526.
View in: PubMed

NOV-002 plus carboplatin in platinum-resistant ovarian cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5593.
View in: PubMed

Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5523.
View in: PubMed

A phase II trial of SNS-595 in women with platinum resistant epithelial ovarian cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5582.
View in: PubMed

Effects of complementary and alternative medicine use on hopelessness in ovarian cancer patients. J Clin Oncol. 2008 May 20; 26(15_suppl):9598.
View in: PubMed

Phase II study of carboplatin and paclitaxel in elderly women with newly diagnosed ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5590.
View in: PubMed

HER pathway gene expression analysis in a phase II study of pertuzumab + gemcitabine vs. gemcitabine + placebo in patients with platinum-resistant epithelial ovarian cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5552.
View in: PubMed

Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):5501.
View in: PubMed

Comparison of the quality of life of early and advanced stage ovarian cancer survivors. J Clin Oncol. 2008 May 20; 26(15_suppl):5528.
View in: PubMed

Long-term adjustment of early-stage ovarian cancer survivors. Int J Gynecol Cancer. 2008 Nov-Dec; 18(6):1183-93.
View in: PubMed

A phase II trial of SNS-595 in women with platinum resistant epithelial ovarian cancer. J Clin Oncol 26. 2008; May 20 suppl(abstr 5582).

Comparison of the quality of life of early and advanced stage ovarian cancer survivors. J Clin Oncol 26. 2008; May 20 suppl(abstr 5528).

Anaphylactic and anaphylactoid reactions to chemotherapy: outcomes and safety of rapid intravenous and intraperitoneal desensitizations in 413 cases. J Clin Oncol 26:. 2008; May 20 suppl(abstr 5526).

Cediranib (AZD2171) is an active agent in recurrent epithelial ovarian cancer. J Clin Oncol 26. 2008; May 20 suppl(abstr 5501).

HER pathway gene expression analysis in a phase II study of pertuzumab + gemcitabine vs. gemcitabine + placebo in patients with platinum-resistant epithelial ovarian cancer. J Clin Oncol 26. 2008; May 20 suppl(abstr 5552).

NOV-002 plus carboplatin in platinum-resistant ovarian cancer. J Clin Oncol 26. 2008; May 20 suppl(abstr 5593).

Effects of complementary and alternative medicine use on hopelessness in ovarian cancer patients. J Clin Oncol 26. 2008; May 20 suppl(abstr 9598).

Combination carboplatin and pemetrexed for the treatment of platinum-sensitive recurrent ovarian cancer. J Clin Oncol 26. 2008; May 20 suppl(abstr 5523).

Phase II study of carboplatin and paclitaxel in elderly women with newly diagnosed ovarian, peritoneal, or fallopian tube cancer. J Clin Oncol 26. 2008; May 20 suppl(abstr 5590).

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol. 2007 Nov 20; 25(33):5180-6.
View in: PubMed

PHASE 3 STUDY: CANFOSFAMIDE (C, TLK286) PLUS CARBOPLATIN (P) VS LIPOSOMAL DOXORUBICIN (D) AS 2ND LINE THERAPY OF PLATINUM (PL) RESISTANT OVARIAN CANCER (OC) . International Journal of Gynecologic Oncology. 2007.

PHASE II STUDY OF CARBOPLATIN AND PEMETREXED FOR THE TREATMENT OF PLATINUM-SENSITIVE RECURRENT OVARIAN CANCER . International Journal of Gynecologic Cancer. 2007.

RESULTS FROM A PHASE II RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND TRIAL SUGGEST IMPROVED PFS WITH THE ADDITION OF PERTUZUMAB TO GEMCITABINE IN PATIENTS WITH PLATINUM-RESISTANT OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER . International Journal of Gynecologic Oncology. 2007.

PHASE I TRIAL OF LIPOSOMAL DOXORUBICIN AND ZD1839 IN PATIENTS WITH REFRACTORY GYNECOLOGICAL MALIGNANCIES OR METASTATIC BREAST CANCER . International Journal Gynecologic Oncology. 2007.

Long term impact of chemotherapy in early stage ovarian cancer survivors. . Submitted to Gyn Oncology. 2007.

Chemotherapy and radiation therapy in UPSC. Journal of Clinical Oncology 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 1. 2007; Vol 25, No. 18S (June 20 Suppl(abstract 5535).

Randomized trial of acupuncture versus sham control for prevention of myelosuppression in patients with gynecologic malignancies. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; Vol 25, No. 18S (June 20 Suppl(abstract 19524).

Results of all-intraperitoneal carboplatin and paclitaxel regimen shows good tolerability and efficacy for advanced ovarian cancer. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; Vol 25, No. 18S (June 20 Suppl(abstract 5521).

Results from a phase II randomized, placebo-controlled, double-blind trial suggest improved PFS with the addition of pertuzumab to gemcitabine in patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; Vol 25, No. 18S (June 20 Suppl(abstract 5507).

Acupuncture for chemotherapy-induced leukopenia: exploratory meta-analysis of randomized controlled trials. J Soc Integr Oncol. 2007; 5(1):1-10.
View in: PubMed

Protein expression and clinical features of ovarian cancer in the elderly. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; Vol 25, No. 18S (June 20 Suppl(Abstract 5574).

Results of all-intraperitoneal carboplatin and paclitaxel regimen shows good tolerability and efficacy for advanced ovarian cancer. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; Vol 25, No. 18S (June 20 Suppl(abstract 5521).

ErbB3 protein expression in serous ovarian carcinomas of elderly women. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings. 2007; Part I. Vol 25, No. 18S (June (abstract 16026).

Safety of maintenance bevacizumab after first-line chemotherapy for advanced ovarian and müllerian cancers. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; Vol 25, No. 18S (June 20 Suppl(abstract 5517).

Integrated report of the phase 2 experience with XL999 administered IV to patients (pts) with NSCLC, renal cell CA (RCC), metastatic colorectal CA (CRC), recurrent ovarian CA, acute myelogenous leaukemia (AML), and multiple myeloma (MM). Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. 2007; Vol 25, No. 18S (June 20 Suppl(Abstract 3591).

A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. Gynecol Oncol. 2007 Mar; 104(3):727-31.
View in: PubMed

Ovarian cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006 Oct; 4(9):912-39.
View in: PubMed

Rational use of cytotoxic chemotherapy for recurrent ovarian cancer. J Natl Compr Canc Netw. 2006 Oct; 4(9):947-53.
View in: PubMed

Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol. 2006 Sep 10; 24(26):4324-32.
View in: PubMed

Three sequential chemotherapy doublets for the treatment of newly diagnosed advanced müllerian malignancies: the modified triple doublet regimen. Gynecol Oncol. 2006 Nov; 103(2):575-80.
View in: PubMed

Phase I trial of liposomal doxorubicin and ZD 1839 in patients with refractory gynecological malignancies or metastatic breast cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5085.
View in: PubMed

A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum-resistant ovarian cancer (OC): Preliminary safety data. J Clin Oncol. 2006 Jun 20; 24(18_suppl):13001.
View in: PubMed

Pharmacokinetic analysis of an all intraperitoneal carboplatin and paclitaxel regimen in ovarian cancer patients demonstrates favorable systemic bioavailability of both agents. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5008.
View in: PubMed

Long-term impact of chemotherapy on early stage ovarian cancer patients. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5024.
View in: PubMed

Phase II trial of GM-CSF in women with asymptomatic müllerian cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5081.
View in: PubMed

Evaluation of serial serum IL-6 levels in women with newly diagnosed ovarian cancer on a prospective clinical trial. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5065.
View in: PubMed

Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced müllerian tumors. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5020.
View in: PubMed

Bevacizumab in patients with advanced platinum-resistant ovarian cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):5006.
View in: PubMed

Negative laparoscopy is highly predictive of negative second-look laparotomy following chemotherapy for ovarian, tubal, and primary peritoneal carcinoma. Gynecol Oncol. 2006 Nov; 103(2):570-4.
View in: PubMed

Phase I/II dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer. Gynecol Oncol. 2006 Oct; 103(1):160-4.
View in: PubMed

Evaluation of serial serum IL-6 levels in women with newly diagnosed ovarian cancer on a prospective clinical trial. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol 24, No. 18S (June 20 Suppl(abstract 5065).

Long-term impact of chemotherapy on early stage ovarian cancer patients. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol 24, No. 18S (June 20 Suppl(abstract 5024).

Pharmacokinetic analysis of an all intraperitoneal carboplatin and paclitaxel regimen in ovarian cancer patients demonstrates favorable systemic bioavailability of both agents. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol 24, No. 18S (June 20 Suppl(abstract 5008).

Phase I/II Dose finding study of combination cisplatin and gemcitabine in patients with recurrent cervix cancer . SGO. 2006; (abstract 161).

A randomized phase II trial with gemcitabine with or without pertuzumab (rhuMAb 2C4) in platinum-resistant ovarian cancer (OC): preliminary safety data. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol 24, No. 18S (June 20 Suppl(abstract 13001).

Phase I trial of liposomal doxorubicin and ZD 1839 in patients with refractory gynecological malignancies or metastatic breast cancer. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol 24, No. 18S (June 20 Suppl(abstract 5085).

Phase II study of carboplatin, paclitaxel and bevacizumab as first line chemotherapy and consolidation for advanced müllerian tumors. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol 24, No. 18S (June 20 Suppl(abstract 5020).

Clinical Activity of Single Agent Pertuzumab (rhuMab 2C4), a HER Dimerization Inhibitor, in Advanced Ovarian Cancer (OC): Potential Predictive Relationship with Tumor HER2 Activation Status. . SGO. 2006; 20(abstract 20).

Bevacizumab in patients with advanced platinum-resistant ovarian cancer. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol 24, No. 18S (June 20 Suppl(abstract 5006).

End of life Care. Muss, Johnson, and Hunter (eds.): Multidisciplinary Treatment and Management of Cancer in the Elderly . 2006.

Phase I trial of liposomal doxorubicin and ZD 1839 in patients with refractory gynecological malignancies or metastatic breast cancer. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol 24, No. 18S (June 20 Suppl(abstract 5085).

Phase II trial of GM-CSF in women with asymptomatic müllerian cancer. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I. 2006; Vol 24, No. 18S (June 20 Suppl(abstract 5081).

Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer. J Pain Symptom Manage. 2005 Dec; 30(6):563-9.
View in: PubMed

A phase II study of irofulven in women with recurrent and heavily pretreated ovarian cancer. Gynecol Oncol. 2006 Apr; 101(1):55-61.
View in: PubMed

A phase II study of fixed dose rate gemcitabine in patients with relapsed müllerian tumors. Int J Gynecol Cancer. 2005 Nov-Dec; 15(6):1035-41.
View in: PubMed

Metaplastic carcinoma of the breast with neuroglial differentiation. Breast. 2006 Aug; 15(4):545-9.
View in: PubMed

Å6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: A phase I trial . Å6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: A phase I trial. 2005; 99(1):50-57.

A6, a urokinase plasminogen activator (uPA)-derived peptide in patients with advanced gynecologic cancer: a phase I trial. Gynecol Oncol. 2005 Oct; 99(1):50-7.
View in: PubMed

Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol. 2005 Nov; 99(2):393-9.
View in: PubMed

A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours. Br J Cancer. 2005 Jul 11; 93(1):54-9.
View in: PubMed

Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res. 2005 Jun 15; 11(12):4430-6.
View in: PubMed

Rapid inpatient and outpatient desensitization for carboplatin or paclitaxel hypersensitivity: A protocol effective in patients with gynecologic malignancies. J Clin Oncol. 2005 Jun; 23(16_suppl):5090.
View in: PubMed

A phase II Trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody in subjects with heavily treated and platinum-resistant advanced Müllerian malignancies. J Clin Oncol. 2005 Jun; 23(16_suppl):3151.
View in: PubMed

Long-acting octreotide for the treatment of symptoms of bowel obstruction in advanced ovarian cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):5159.
View in: PubMed

A phase II trial of modified triple doublets for the treatment of advanced Müllerian malignancies. J Clin Oncol. 2005 Jun; 23(16_suppl):5010.
View in: PubMed

Phase II trial of anastrazole in combination with gefitinib in women with asymptomatic mullerian cancer. J Clin Oncol. 2005 Jun; 23(16_suppl):5063.
View in: PubMed

Cancer of the ovary. N Engl J Med. 2005 Mar 24; 352(12):1268-9; author reply 1268-9.
View in: PubMed

Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol Oncol. 2005 Mar; 96(3):824-9.
View in: PubMed

Long-acting octreotide (Sandostatin LAR®Depot) for the treatment of symptoms of bowel obstruction in advanced ovarian cancer. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. 2005; Vol 23, No. 16S, Part I of II (abstract 5159).

Clinical activity of pertuzumab (rhuMab 2C4) in advanced, refractory or recurrent ovarian cancer (OC), and the role of HER2 activation status. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. 2005; Vol 23, No. 16S, Part I of II (abstract 5051).

A Phase II Trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody in subjects with heavily treated and platinum-resistant advanced Müllerian malignancies. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. 2005; Vol 23, No. 16S, Part I of II (abstract 3151).

Phase II Trial of Anastrazole in Combination with Gefitinib in Women with Asymptomatic Mullerian Cancer. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. 2005; Vol 23, No. 16S, Part I of II (abstract 5063).

A phase II trial of modified triple doublets for the treatment of advanced Müllerian malignancies. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. 2005; Vol 23, No. 16S, Part I of II (abstract 5010).

Rapid inpatient and outpatient desensitization for carboplatin or paclitaxel hypersensitivity: a protocol effective in patients with gynecologic malignancies. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. 2005; Vol 23, No. 16S, Part I of II (abstract 5090).

A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer. Gynecol Oncol. 2005 Jan; 96(1):198-203.
View in: PubMed

Rapid inpatient and outpatient desensitization for carboplatin or paclitaxel hypersensitivity: a protocol effective in patients with gynecologic malignancies. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. 2005; Vol 23, No. 16S, Part I of II (abstract 5090).

A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer . Gynecologic Onlology. 2004; 95(3):624-631.

A phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. Gynecol Oncol. 2004 Dec; 95(3):624-31.
View in: PubMed

Ovarian cancer clinical practice guidelines. J Natl Compr Canc Netw. 2004 Nov; 2(6):526-47.
View in: PubMed

Carboplatin hypersensitivity: a 6-h 12-step protocol effective in 35 desensitizations in patients with gynecological malignancies and mast cell/IgE-mediated reactions. Gynecol Oncol. 2004 Nov; 95(2):370-6.
View in: PubMed

Efficacy of epoetin alfa in a retrospective non-stratified subgroup analysis of a breast cancer cohort receiving non-platinum chemotherapy. Tumori. 2004 Sep-Oct; 90(5):449-57.
View in: PubMed

Attitudes to chemotherapy in patients with ovarian cancer. Gynecol Oncol. 2004 Aug; 94(2):427-35.
View in: PubMed

A phase II study of fixed dose-rate gemcitabine in patients with relapsed Müllerian tumors. J Clin Oncol. 2004 Jul 15; 22(14_suppl):5151.
View in: PubMed

Long-acting octreotide for the treatment of symptoms of bowel obstruction and intermittent obstruction in advanced ovarian cancer. J Clin Oncol. 2004 Jul 15; 22(14_suppl):5148.
View in: PubMed

Phase I trial of escalating doses of topotecan in combination with a fixed dose of pegylated liposomal doxorubicin in women with müllerian malignancies. Gynecol Oncol. 2004 Jun; 93(3):702-7.
View in: PubMed

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004 Apr 15; 22(8):1480-90.
View in: PubMed

End of life issues in older patients. Semin Oncol. 2004 Apr; 31(2):274-81.
View in: PubMed

A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer. Gynecol Oncol. 2004 Apr; 93(1):229-32.
View in: PubMed

A phase II study of fixed dose-rate gemcitabine in patients with relapsed Müllerian tumors. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004; Vol 22, No 14S (July 15 Supple(abstract 5151).

Long-acting octreotide for the treatment of symptoms of bowel obstruction and intermittent obstruction in advanced ovarian cancer. Journal of Clinical Oncology, 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). 2004; Vol 22, No 14S (July 15 Supple(abstract 5148).

Phase II trial of anastrozole in women with asymptomatic müllerian cancer. Gynecol Oncol. 2003 Dec; 91(3):596-602.
View in: PubMed

A phase II trial of three sequential doublets for the treatment of advanced müllerian malignancies. Gynecol Oncol. 2003 Nov; 91(2):293-8.
View in: PubMed

Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors. Gynecol Oncol. 2003 Sep; 90(3):610-8.
View in: PubMed

Attitudes to chemotherapy in patients with ovarian cancer. Proc Am Soc Clin Oncol. 2003; 22(abstract abstr 1888).

Phase I study of cisplatin and gemcitabine for recurrent cervix cancer following primary radiotherapy or newly diagnosed metastatic cervix cancer. Proc Am Soc Clin Oncol. 2003; 22(abstr 1872).

Gynecologic Cancers. Atlas of Diagnostic Oncology, Arthur Skarin, editor. 2003.

Significance of Positive Peritoneal Cytology in Women with Endometrial Cancer. ACS Endometrial Cancer. 2003.

A phase II study of the MDR inhibitor biricodar (INCEL, VX-710) and paclitaxel in women with advanced ovarian cancer refractory to paclitaxel therapy. Gynecol Oncol. 2002 Sep; 86(3):302-10.
View in: PubMed

Breast cancer screening in women previously treated for Hodgkin's disease: a prospective cohort study. J Clin Oncol. 2002 Apr 15; 20(8):2085-91.
View in: PubMed

A phase I study of vaccination with lethally irradiated, autologous ovarian cancer cells engineered by adenoviral mediated gene transfer to secrete human granulocyte-macrophage colony stimulating factor (GVAX). Proc Am Soc Clin Oncol. 2002; 21(abstr 1840).

A Phase I trial of continual sequential oral etoposide and infusional topotecan. Proc Am Soc Clin Oncol. 2002; 21(abstr 2168).

A Phase I-II study of 96-hour infusional topotecan and paclitaxel for patients with recurrent Müllerian tumors. Cancer. 2001 Sep 01; 92(5):1156-67.
View in: PubMed

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001 May 15; 19(10):2722-30.
View in: PubMed

The clinical utility of liposomal doxorubicin in recurrent ovarian cancer. Gynecol Oncol. 2001 May; 81(2):206-12.
View in: PubMed

A Phase II and Pharmacokinetic/Dynamic Study of Doxil and Weekly Paclitaxel Chemotherapy for Recurrent Müllerian Tumors. Proc Am Soc Clin Oncol. 2001; 20(abstr 2524).

Triple Doublet Chemotherapy for the Treatment of Mullerian Malignancies. Proc Am Soc Clin Oncol. 2001; 20(abstr 846).

Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer. Gynecol Oncol. 2000 May; 77(2):271-7.
View in: PubMed

Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000 Mar; 18(6):1212-9.
View in: PubMed

Herceptin and Vinorelbine for HER2-Positive Metastatic Breast Cancer: A Phase II Study. Proc Am Soc Clin Oncol. 2000; 19(abstr 392).

Phase I Study of Cisplatin and Gemcitabine for Recurrent Cervix Cancer Following Primary Radiotherapy. Proc Am Soc Clin Oncol. 2000; 19(abstr 1571).

A Phase I Study of Cyclophosphamide, Doxorubicin, and Eniluracil/5-FU in Women with Advanced Breast Cancer: Preliminary Results. Proc Am Soc Clin Oncol. 2000; 19(abstr 444).

A Phase II and Pharmacokinetic/Dynamic Study of Doxil and Weekly Paclitaxel Chemotherapy for Recurrent Müllerian Tumors. Proc Am Soc Clin Oncol. 2000; 19(abstr 1623).

A Phase I/II and Pharmacokinetic Study of 96-Hour Infusional Topotecan and Paclitaxel Chemotherapy for Recurrent Müllerian Tumors. Proc Am Soc Clin Oncol. 2000; 19(abstr 1552).

Cytokines IL-1beta, IL-2, IL-6, IL-8, MCP-1, GM-CSF and TNFalpha in patients with epithelial ovarian cancer and their relationship to treatment with paclitaxel. Int J Gynecol Cancer. 2000 Jan; 10(1):33-41.
View in: PubMed

Phase I study of Doxil and vinorelbine in metastatic breast cancer. Ann Oncol. 1999 Sep; 10(9):1113-6.
View in: PubMed

A Phase I/II and Pharmacokinetic Study of 96 Hour Infusional Topotecan and Paclitaxel Chemotherapy for Relapsed Epithelial Ovarian Cancer. (Meeting abstract). 1999 ASCO Meeting. 1999; ASCO Meeting(abstract 1477).

A Phase I Study of Carboplatin, Taxol[Superscript TM], Etoposide, and Cyclophosphamide (CTEC) with Filgrastim as First-Line Therapy for Patients with Advanced Epithelial Ovarian Cancer (Meeting abstract). 1999 Asco Meeting. 1999; ASCO(abstract 1417).

A Retrospective Analysis of the Clinical Utility of Doxil in Recurrent Ovarian Cancer (ROC). (Meeting abstract). 1999 ASCO Meeting. 1999; ASCO Meeting(abstract 1434).

Breast Cancer: Modifiable Lifestyle Risk Factors, in Lifestyle Medicine. Editor: James M. Rippe. 1999.

Weekly Docetaxel (Taxotere[trade]) for Metastatic Breast Cancer: A Phase II Trial (Meeting abstract). 1999 ASCO Meeting. 1999; ASCO Meeting(abstract 484).

Inability to escalate vinorelbine dose intensity using a daily x3 schedule with and without filgrastim in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 1999; 43(1):68-72.
View in: PubMed

The Molecular Basis of Cancer: A review. Oncology. 1996; 10:71.

B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. J Immunol. 1996 Feb 01; 156(3):1126-31.
View in: PubMed

Breast cancer screening in young women who have been treated for Hodgkin's disease (Meeting abstract). 1996 ASCO Meeting. 1996; ASCO Meeting(abstract 1659).

Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood. 1995 May 01; 85(9):2507-15.
View in: PubMed

Factor independence of human myeloid leukemia cell lines is associated with increased phosphorylation of the proto-oncogene Raf-1. Exp Hematol. 1994 Oct; 22(11):1111-7.
View in: PubMed

Autologous peripheral stem cell transplantation of the blastic phase of chronic myeloid leukemia following sequential high-dose cytosine arabinoside and melphalan. Am J Hematol. 1994 Apr; 45(4):283-7.
View in: PubMed

Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Exp Hematol. 1993 Oct; 21(11):1460-6.
View in: PubMed

Prevention of Legionella infections in a bone marrow transplant unit: multifaceted approach to decontamination of a water system. Infect Control Hosp Epidemiol. 1993 Oct; 14(10):571-5.
View in: PubMed

Tyrosine phosphorylation of rasGAP and associated proteins in chronic myelogenous leukemia cell lines. Blood. 1992 May 01; 79(9):2215-20.
View in: PubMed

Stereologic analysis of monocytes and their subcellular organelles in patients with acute monocytic and myelomonocytic leukemia. Lab Invest. 1990 Sep; 63(3):405-12.
View in: PubMed

Stereologic Analysis of Monocytes and their Subcellular Organelles in patients wit acute monocytic and myelomonocytic leukemia. . Laboratory Investigation. 1990; 63(3):405-12.

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Dana-Farber Cancer Institute - Chestnut Hill
300 Boylston Street
Newton, MA 02459
Get Directions

Ratings

Top